Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, outlines a post-hoc analysis of the ACTIVATE (NCT03559699) trial and its long-term extension study (NCT03853798) assessing the now-approved pyruvate kinase (PK) activator mitapivat for PK deficiency. The trial met all its primary and secondary endpoints, improving hemolytic factors and quality of life (QoL). The analysis showed that patients receiving the drug were more able to achieve daily tasks such as attending work and school, significantly improving their health-related QoL. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
